Assembly Biosciences to Present at the Jefferies London Healthcare Conference Wed, 08 Nov 2017 12:00:00 +0000 INDIANAPOLIS, Nov. 08, 2017-- Assembly Biosciences, Inc., a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus infection and novel oral ...
Assembly Biosciences Announces Pricing of $60 Million Offering of Common Stock Thu, 02 Nov 2017 04:40:53 +0000 INDIANAPOLIS, Nov. 02, 2017-- Assembly Biosciences, Inc., a clinical-stage biotechnology company advancing a new class of oral therapeutic candidates for the treatment of hepatitis B virus infection and ...
Assembly Biosciences Announces Proposed Underwritten Offering of Common Stock Wed, 01 Nov 2017 20:01:00 +0000 INDIANAPOLIS, Nov. 01, 2017-- Assembly Biosciences, Inc., a clinical-stage biotechnology company advancing a new class of oral therapeutic candidates for the treatment of hepatitis B virus infection and ...
Assembly Biosciences, Inc. – Value Analysis (NASDAQ:ASMB) : October 26, 2017 Thu, 26 Oct 2017 15:01:04 +0000 Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Assembly Biosciences, Inc. a score of 33. Our analysis is based on comparing Assembly Biosciences, Inc. with the following peers – Ironwood Pharmaceuticals, Inc. Class A, Ocera Therapeutics, Inc., Synergy Pharmaceuticals, Inc., Conatus Pharmaceuticals Inc., Enzon Pharmaceuticals, Inc., Orexigen Therapeutics, Inc., Progenics Pharmaceuticals, Inc. and Sucampo Pharmaceuticals, ... Read more
(Read more...)
Assembly Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : ASMB-US : October 25, 2017 Wed, 25 Oct 2017 12:14:43 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Assembly Biosciences, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
Assembly Biosciences Announces 2017 AASLD Presentations Mon, 02 Oct 2017 11:00:00 +0000 INDIANAPOLIS, Oct. 02, 2017-- Assembly Biosciences, Inc., a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus infection and novel oral ...
3 Biotech Stocks to Be Thankful for This Year Sun, 19 Nov 2017 16:43:00 +0000 If you notice a relative who can't stop grinning at the Thanksgiving dinner table, they're probably holding shares of these biotech stocks.
Ligand (LGND) Q3 Earnings & Revenues Top, 2017 View Raised Fri, 10 Nov 2017 15:52:03 +0000 Ligand's (LGND) earnings and revenues beat estimates. Total revenues also rise year over year on the back of higher royalty benefits. The company ups its guidance for 2017.
Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2017 London Healthcare Conference on November 15th Wed, 08 Nov 2017 12:00:00 +0000 Spectrum Pharmaceuticals, Inc. , a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the Jefferies 2017 London Healthcare Conference being held at the Waldorf Hilton in London.
Spectrum Pharmaceuticals Reports Third Quarter 2017 Financial Results and Pipeline Update Thu, 02 Nov 2017 20:02:00 +0000 Spectrum Pharmaceuticals, Inc. , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology announced today financial results for the three-month period ended September 30, 2017.
What’s Johnson & Johnson’s Valuation? Fri, 24 Nov 2017 18:30:56 +0000 As of November 21, 2017, Johnson & Johnson was trading at a forward PE multiple of ~17.6x as compared to the industry average of 16.2x.
Value-Adding Dividend Stocks To Buy Now Fri, 24 Nov 2017 13:02:22 +0000 A great investment for income investors with a long time horizon is in dividend-paying companies like Pfizer. Dividend stocks are a safe bet to increase your portfolio value as theyRead More...
Top 10 Largest Pharmaceutical Companies By Revenue in 2017 Thu, 23 Nov 2017 14:00:14 +0000 The top 10 largest pharmaceutical companies by revenue in 2017 are leading companies that have a large geographical presence, loyal customer base and technologically advanced manufacturing and R&D facilities. Though their businesses are recession-proof, a huge portion of their expenses has to be allocated to research and development to stay ahead of the competition. Medicine has […]
How Teva’s Generic Medicines Business Is Positioned after 3Q17 Wed, 22 Nov 2017 19:30:10 +0000 Teva's Generic Medicine segment generated 3Q17 revenues of $3.0 billion, which was ~8% higher YoY (year-over-year) but ~2% lower QoQ (quarter-over-quarter).
8 Bitcoin Stocks That You Won’t Lose Your Shirt Over Tue, 21 Nov 2017 16:59:45 +0000 Bitcoin may not have the trust of Wall Street institutions just yet, but millennials are all in. Blockchain Capital recently conducted a study of 2,000 millennials (aged 18-34) and asked them to make a theoretical choice between owning $1,000 in bonds or stocks and $1,000 in bitcoin. It seems millennials are laughing all the way to the decentralized blockchain.
November Pharma And Biotech Dividend Stocks To Look Out For Tue, 21 Nov 2017 13:03:25 +0000 Regularly affected by the ever-changing regulatory environment, the pharmaceutical and biotech industry is not one for producing the most stable cash flow. Thus, investors don’t usually associate this industry withRead More...
Is Merck & Co. Inc. a Buy? Tue, 21 Nov 2017 11:12:00 +0000 Merck just might be poised for a rebound. But is the stock a smart long-term pick?
3 Companies Competing to Gain Lead in Ovarian Cancer Market Fri, 24 Nov 2017 16:24:04 +0000 Three companies including a major pharma player are developing drugs for the treatment of ovarian cancer using a new technology instead of chemotherapy and competing to gain market share.
Will New Drug Approvals Boost Novartis (NVS) Portfolio? Fri, 24 Nov 2017 13:38:01 +0000 Novartis (NVS) is facing stiff generic competition for key drugs. Nevertheless, we expect approval of new drugs to boost its portfolio.
Top 10 Largest Pharmaceutical Companies By Revenue in 2017 Thu, 23 Nov 2017 14:00:14 +0000 The top 10 largest pharmaceutical companies by revenue in 2017 are leading companies that have a large geographical presence, loyal customer base and technologically advanced manufacturing and R&D facilities. Though their businesses are recession-proof, a huge portion of their expenses has to be allocated to research and development to stay ahead of the competition. Medicine has […]
ETFs with exposure to AbbVie, Inc. : November 20, 2017 Mon, 20 Nov 2017 16:21:37 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AbbVie, Inc. Here are 5 ETFs with the largest exposure to ABBV-US. Comparing the performance and risk of AbbVie, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
(Read more...)
Roche's (RHHBY) Hemophilia A Drug Receives FDA Approval Fri, 17 Nov 2017 14:05:02 +0000 Roche (RHHBY) hematology portfolio got a boost when the FDA approved Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors.
Cramer applauds Miles White, Abbott CEO Thu, 16 Nov 2017 23:54:00 +0000 Jim Cramer zoomed in on the track record of Abbott CEO Miles White, who has transformed the pharmaceutical company since he took over in 1999.
Understanding Abbott’s Alere Acquisition: What We Can Expect Fri, 24 Nov 2017 15:31:24 +0000 On October 3, 2017, Abbott announced the completion of its acquisition of Alere, which has had troubles since the initial announcement in February 2016.
Inside Abbott’s Neuromodulation Business Growth Fri, 24 Nov 2017 14:01:31 +0000 Abbott's Medical Devices segment has products for rhythm management, heart failure, electrophysiology, structural heart diseases, neuromodulation, and more.
Should You Sell Abbott Laboratories (ABT) At This PE Ratio? Thu, 23 Nov 2017 16:01:04 +0000 Abbott Laboratories (NYSE:ABT) trades with a trailing P/E of 47.4x, which is higher than the industry average of 41.8x. Although some investors may jump to the conclusion that you shouldRead More...
Inside Abbott’s Growth: Understanding the Major Drivers Thu, 23 Nov 2017 12:34:23 +0000 Abbott Laboratories (ABT) registered sales of ~$6.8 billion for 3Q17, which represents YoY (year-over-year) sales growth of ~28.8% on a reported basis.
Abbott on the Street: Analyst Recommendations Wed, 22 Nov 2017 21:51:56 +0000 Abbott registered strong 3Q17 results, surpassing estimates for both sales and earnings and reporting healthy growth across all of its business segments.
ETFs with exposure to Abbott Laboratories : November 20, 2017 Mon, 20 Nov 2017 16:22:26 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Abbott Laboratories Here are 5 ETFs with the largest exposure to ABT-US. Comparing the performance and risk of Abbott Laboratories with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
(Read more...)
Trade of the Day: Abbott Laboratories (ABT) Mon, 20 Nov 2017 13:57:00 +0000 To receive further updates on this Abbott Laboratories (NYSE:ABT) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of SlingShot Trader today.
Zogenix is a specialty pharmaceutical company whose goal is to uniquely enhance and differentiate medicines by incorporating innovative technologies in an effort to relieve suffering in people with CNS and pain disorders.
Zogenix to Present at Stifel 2017 Healthcare Conference Tue, 14 Nov 2017 13:00:00 +0000 EMERYVILLE, Calif., Nov. 14, 2017-- Zogenix, Inc., a pharmaceutical company developing therapies for the treatment of rare central nervous system disorders, today announced that Stephen J. Farr, Ph.D., ...
Zogenix Provides Corporate Update and Reports Third Quarter 2017 Financial Results Tue, 07 Nov 2017 21:01:00 +0000 During the third quarter, the Company announced positive top-line results from its Phase 3 Study 1 of ZX008 in patients with Dravet syndrome Study 1 met primary endpoint of reduction in frequency of convulsive ...
Zogenix, Inc. to Host Earnings Call Tue, 07 Nov 2017 17:00:00 +0000 NEW YORK, NY / ACCESSWIRE / November 7, 2017 / Zogenix, Inc. (NASDAQ: ZGNX ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 7, 2017 at 4:30 PM Eastern Time. ...
ETFs with exposure to Zogenix, Inc. : October 27, 2017 Fri, 27 Oct 2017 15:24:28 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Zogenix, Inc. Here are 5 ETFs with the largest exposure to ZGNX-US. Comparing the performance and risk of Zogenix, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
(Read more...)
How Johnson & Johnson’s Revenues Trended in 3Q17 Fri, 24 Nov 2017 21:35:11 +0000 Johnson & Johnson (JNJ) reported revenue growth of 10.3% to $19.7 billion during 3Q17 as compared to $17.8 billion during 3Q16.
Johnson & Johnson Reports Revenue Growth in 3Q17 Fri, 24 Nov 2017 20:05:19 +0000 Johnson & Johnson (JNJ) reported 10.3% growth in its revenues to $19.7 billion during 3Q17, as compared to revenues of $17.8 billion in 3Q16.
Cancer Space Update: 2 Drugs Receive Regulatory Nod in EU Fri, 24 Nov 2017 18:59:06 +0000 This week the European Commission granted approval to Zejula for ovarian cancer and for label expansion of Tasigna in first-line Ph+ chronic myeloid leukemia.
What’s Johnson & Johnson’s Valuation? Fri, 24 Nov 2017 18:30:56 +0000 As of November 21, 2017, Johnson & Johnson was trading at a forward PE multiple of ~17.6x as compared to the industry average of 16.2x.
How to Diversify Your Healthcare Investments Fri, 24 Nov 2017 14:37:00 +0000 In an all-too-often boom-or-bust sector like healthcare, it’s critical to make sure you’re diversifying your bets wisely.
Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan Thu, 16 Nov 2017 21:01:00 +0000 Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced the commencement of patient dosing in its Phase 2 clinical trial designed in accordance with the requirements of Japan’s PMDA for potential regulatory ...
Aerie reports 3Q loss Wed, 08 Nov 2017 21:07:32 +0000 On a per-share basis, the Irvine, California-based company said it had a loss of 89 cents. Losses, adjusted for stock option expense, were 71 cents per share. Aerie shares have increased 68 percent since ...
Aerie Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update Wed, 08 Nov 2017 21:01:00 +0000 Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the third quarter ended September 30, 2017, along with a general business update.
Aerie Pharmaceuticals, Inc. to Host Earnings Call Wed, 08 Nov 2017 20:10:00 +0000 NEW YORK, NY / ACCESSWIRE / November 8, 2017 / Aerie Pharmaceuticals, Inc. (NASDAQ: AERI ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 5:00 PM ...
Is a Surprise Coming for Aerie (AERI) This Earnings Season? Tue, 07 Nov 2017 13:36:01 +0000 Aerie Pharmaceuticals (AERI) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Aerie Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference Tue, 07 Nov 2017 12:30:00 +0000 Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside chat discussion at the Stifel 2017 Healthcare Conference ...
Flexion Therapeutics Named Top Place to Work for 2017 by The Boston Globe Fri, 17 Nov 2017 14:00:00 +0000 Annual survey recognizes and honors the best employers in Massachusetts BURLINGTON, Mass., Nov. 17, 2017-- Flexion Therapeutics, Inc. today announced that it has been named one of the Top Places to Work ...
Is There Now An Opportunity In Flexion Therapeutics Inc (FLXN)? Tue, 07 Nov 2017 18:23:32 +0000 Flexion Therapeutics Inc (NASDAQ:FLXN), a biotechnology company based in United States, saw a double-digit share price rise of over 10% in the past couple of months on the NasdaqGM. AsRead More...
Stocks on My Radar on This Selling Wed, 25 Oct 2017 17:18:00 +0000 I'm always excited about the potential for new trades when we have selling like this.
Flexion's Latest FDA Approval Reignites Takeover Chatter Sun, 15 Oct 2017 21:00:00 +0000 The Burlington, Mass.-based pharmaceutical firm on Oct. 6 secured approval from the Food and Drug Administration for its osteoarthritis knee pain treatment Zilretta, a non-opioid medicine.
As Brexit looms, UK pitches new industry plan, wins support from Merck, Qiagen Mon, 27 Nov 2017 08:56:55 +0000 Britain pitched a new strategy for industry on Monday that sees greater state intervention to tackle weak productivity and to help the world's sixth largest economy cope with the upheaval of leaving the European Union. Prime Minister Theresa May first flagged the plan in January, seven months after Britain voted to leave the European Union, adopting a hands-on approach to business that had largely been abandoned by her predecessors from the time of Margaret Thatcher in the 1980s. The government said it had secured major investments from global healthcare company MSD, known as Merck & Co in the United States, and German-based diagnostics company Qiagen ahead of the publication of the strategy.
UK launches plan for industry as Brexit looms, wins Merck investment Mon, 27 Nov 2017 00:01:00 +0000 The British government launched a new strategy for industry on Monday, aiming to intervene in key sectors to tackle weak productivity and bolster businesses to counter any new problems caused by Brexit. Prime Minister Theresa May first flagged the plan in January, seven months after Britain voted to leave the European Union, adopting a hands-on approach to business that had largely been abandoned by her predecessors from the time of Margaret Thatcher in the 1980s. Business Minister Greg Clark said Britain has some of the world's best universities and research institutions, as well as leading companies in sectors ranging from advanced manufacturing to financial services, life sciences and creative industries.
U.K. Seeks to Take Sting Out of Brexit With Industrial Strategy Mon, 27 Nov 2017 00:01:00 +0000 Business Secretary Greg Clark said reviving Britain’s flagging productivity lies at the heart of the industrial strategy he’ll unveil on Monday to help chart the future of Britain’s economy as the country ...
3 Companies Competing to Gain Lead in Ovarian Cancer Market Fri, 24 Nov 2017 16:24:04 +0000 Three companies including a major pharma player are developing drugs for the treatment of ovarian cancer using a new technology instead of chemotherapy and competing to gain market share.
52-Week Company Lows Fri, 24 Nov 2017 15:44:46 +0000 Details the 52-week lows of the following companies: General Electric, Merck & Co., Schlumberger, Kinder Morgan, Williams Companies and Archer-Daniels Midland
Top 10 Largest Pharmaceutical Companies By Revenue in 2017 Thu, 23 Nov 2017 14:00:14 +0000 The top 10 largest pharmaceutical companies by revenue in 2017 are leading companies that have a large geographical presence, loyal customer base and technologically advanced manufacturing and R&D facilities. Though their businesses are recession-proof, a huge portion of their expenses has to be allocated to research and development to stay ahead of the competition. Medicine has […]
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.
Accum/Dist: 2.07 (median winner: 1.53)
Liquidity: 0.60% (median winner: 1.18%)
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.